Carebastine Almirall Prodesfarma.
Carebastine, a histamine H1 antagonist, is under development by Almirall Prodesfarma for the potential treatment of allergic rhinitis, asthma and conjunctivitis. A nasal formulation was submitted for registration in Spain in June 1999 [343595]. It is also in phase III trials for conjunctivitis and phase I trials for asthma [343144,343243]. In a multicentered, multinational, double-blind, placebo-controlled study in patients with symptomatic SAR, patients were assigned a nasal spray formulation of carebastine (2.5 mg/ml) or placebo. Severity scores decreased significantly with carebastine compared to placebo. This findings suggest that carebastine nasal spray has the potential to be of value in the treatment of SAR [282185]. In a multicenter, multinational, double-blind, randomized, placebo-controlled study, patients with seasonal allergic conjunctivitis (SAC) were assigned an eye drop formulation of carebastine (25 mg/ml) or placebo. Carebastine was significantly better than placebo at relieving the effects of SAC, as early as 15 min after administration and the effect lasted for 14 days. Carebastine was well-tolerated and there were no difference in adverse events between the two groups [282897].
University Hospital Aintree, University Clinical Department, Long Moor Lane, Liverpool, L9 7AL, UK. pkingham@liverpool.ac.uk
P
P
Kingham
D000818:Animals; D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D001249:Asthma / Q000188:drug therapy*; D002090:Butyrophenones / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D002986:Clinical Trials as Topic; D000075202:Contraindications; D015507:Drugs, Investigational / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans; D010880:Piperidines / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D013329:Structure-Activity Relationship
D018927:Anti-Asthmatic Agents; D002090:Butyrophenones; D015507:Drugs, Investigational; D010880:Piperidines; C058251:carebastine